Randomized Phase III trial: Maintenance therapy with the monoclonal chimeric antibody rituximab compared to observation in patients with CD20+ B-cell Non-Hodgkins lymphoma

Trial Profile

Randomized Phase III trial: Maintenance therapy with the monoclonal chimeric antibody rituximab compared to observation in patients with CD20+ B-cell Non-Hodgkins lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 12 Jun 2011 Final results presented at the 16th Congress of the European Hematology Association.
    • 12 Mar 2009 Status changed from not stated to completed.
    • 01 Jan 2009 Results were published in the Annals of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top